To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04393753
Title Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1 (MERKLIN2)
Acronym MERKLIN2
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors 4SC AG
Indications
Therapies
Age Groups: adult | senior
Covered Countries NLD | ITA | FRA | ESP | DEU | BEL


No variant requirements are available.